RU2004128238A - Применение ингибитора или антагониста тканевого фактора - Google Patents
Применение ингибитора или антагониста тканевого фактора Download PDFInfo
- Publication number
- RU2004128238A RU2004128238A RU2004128238/15A RU2004128238A RU2004128238A RU 2004128238 A RU2004128238 A RU 2004128238A RU 2004128238/15 A RU2004128238/15 A RU 2004128238/15A RU 2004128238 A RU2004128238 A RU 2004128238A RU 2004128238 A RU2004128238 A RU 2004128238A
- Authority
- RU
- Russia
- Prior art keywords
- use according
- inhibitor
- antagonist
- diabetes
- insulin
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 10
- 239000005557 antagonist Substances 0.000 title claims 8
- 108010000499 Thromboplastin Proteins 0.000 title claims 3
- 102000002262 Thromboplastin Human genes 0.000 title claims 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 7
- 206010012601 diabetes mellitus Diseases 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000004153 islets of langerhan Anatomy 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 101150025711 TF gene Proteins 0.000 claims 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims 1
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000015337 arteriosclerotic cardiovascular disease Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 239000004026 insulin derivative Substances 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 239000003868 thrombin inhibitor Substances 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1. Применение ингибитора или антагониста тканевого фактора, TF, в приготовлении лекарственного средства для лечения или предупреждения диабета или связанных с диабетом заболеваний.
2. Применение по п.1 в приготовлении лекарственного средства для введения в связи с трансплантацией инсулинпродуцирующих клеток пациентам с инсулинзависимым сахарным диабетом.
3. Применение по п.1 в приготовлении лекарственного средства для лечения сердечно-сосудистых заболеваний и/или артериосклероза.
4. Применение по п.3 для лечения пациентов с диабетом типа П или предшествующих ему стадий.
5. Применение по любому из предыдущих пунктов, где ингибитор или антагонист TF является анти-TF-антителом, имеющим биологический эффект связывания TF.
6. Применение по любому из пп.1-4, где этот ингибитор является веществом, ингибирующим выработку и/или высвобождение TF из островков Лангерганса.
7. Применение по любому из пп.1-4, где ингибитор или антагонист TF является агентом, способным блокировать синтез TF.
8. Применение по п.7, где этот агент является антисмысловой конструкцией, блокирующей ген TF.
9. Применение по любому из пп.1-4, где вещество, ингибирующее выработку и/или высвобождение TF, характеризуется уменьшением выработки инсулина в островках Лангерганса.
10. Применение по п.9, где это вещество является инсулином или аналогом инсулина.
11. Применение по любому из пп.1-4, где ингибитор или антагонист TF используют в комбинации с антикоагулянтом, таким как гепарин или его фракции или производные.
12. Применение по любому из пп.1-4, где ингибитор или антагонист TF используют в комбинации с ингибитором тромбина.
13. Применение по любому из пп.1-4, где ингибитор или антагонист TF используют в комбинации с ингибитором тромбоцитов.
14. Способ лечения или предупреждения диабета или связанных с диабетом заболеваний, предусматривающий введение ингибитора или антагониста тканевого фактора, TF, субъекту, нуждающемуся в этом.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0200545A SE0200545D0 (sv) | 2002-02-22 | 2002-02-22 | Use of an inhibitor or antagonist against tissue factor |
| SE0200545-2 | 2002-02-22 | ||
| SE0203540A SE0203540D0 (sv) | 2002-02-21 | 2002-11-28 | Use of an inhibilor or antagonist against lissue factor |
| SE0203540-0 | 2002-11-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2004128238A true RU2004128238A (ru) | 2005-05-20 |
| RU2315621C2 RU2315621C2 (ru) | 2008-01-27 |
Family
ID=27759837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004128238/15A RU2315621C2 (ru) | 2002-02-22 | 2003-02-21 | Применение ингибитора или антагониста тканевого фактора |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050255111A1 (ru) |
| EP (1) | EP1476186A1 (ru) |
| JP (1) | JP2005528343A (ru) |
| KR (1) | KR20050004785A (ru) |
| CN (1) | CN1646162A (ru) |
| AP (1) | AP2004003113A0 (ru) |
| AU (1) | AU2003206571A1 (ru) |
| CA (1) | CA2476832A1 (ru) |
| CO (1) | CO5611170A2 (ru) |
| IL (1) | IL163605A0 (ru) |
| MX (1) | MXPA04008061A (ru) |
| NO (1) | NO20043960L (ru) |
| NZ (1) | NZ535199A (ru) |
| RU (1) | RU2315621C2 (ru) |
| TN (1) | TNSN04160A1 (ru) |
| WO (1) | WO2003070275A1 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| SMT201700547T1 (it) | 2010-06-15 | 2018-01-11 | Genmab As | Coniugati di farmaco anticorpo umano contro il fattore tissutale |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| TW202010755A (zh) | 2018-05-07 | 2020-03-16 | 丹麥商珍美寶股份有限公司 | 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| CN115944738B (zh) * | 2022-12-13 | 2024-06-18 | 华中科技大学同济医学院附属同济医院 | 补体c3裂解抑制剂在制备治疗糖尿病心肌病的药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506134A (en) * | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| US5725854A (en) * | 1994-04-13 | 1998-03-10 | Research Corporation Technologies, Inc. | Methods of treating disease using sertoli cells an allografts or xenografts |
| PT833911E (pt) * | 1995-06-07 | 2004-09-30 | Ortho Mcneil Pharm Inc | Anticorpos anti-factor tecidular enxertados com cdr e metodos para a sua utilizacao |
| GB9606452D0 (en) * | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
| US5981471A (en) * | 1997-02-06 | 1999-11-09 | Entremed, Inc. | Compositions and methods for inhibiting cellular proliferation |
| US5986065A (en) * | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
| US6387366B1 (en) * | 1998-12-31 | 2002-05-14 | Alg Company | Methods for reducing adverse side effects associated with cellular transplantation |
| KR20070049251A (ko) * | 1999-10-27 | 2007-05-10 | 타녹스 인코퍼레이티드 | 조직 인자 길항제 및 그의 사용 방법 |
| AU2001250814B2 (en) * | 2000-03-16 | 2007-02-15 | Genentech, Inc. | Anti-tissue factor antibodies with enhanced anticoagulant potency |
| US6579531B2 (en) * | 2000-06-16 | 2003-06-17 | Thomas T. Aoki | Method for treating heart disease and cardiovascular disease in diabetic and non-diabetic patients |
-
2003
- 2003-02-21 WO PCT/SE2003/000289 patent/WO2003070275A1/en not_active Ceased
- 2003-02-21 AP APAP/P/2004/003113A patent/AP2004003113A0/en unknown
- 2003-02-21 KR KR10-2004-7013097A patent/KR20050004785A/ko not_active Ceased
- 2003-02-21 CN CNA038090651A patent/CN1646162A/zh active Pending
- 2003-02-21 AU AU2003206571A patent/AU2003206571A1/en not_active Abandoned
- 2003-02-21 NZ NZ535199A patent/NZ535199A/xx unknown
- 2003-02-21 EP EP03705622A patent/EP1476186A1/en not_active Withdrawn
- 2003-02-21 MX MXPA04008061A patent/MXPA04008061A/es not_active Application Discontinuation
- 2003-02-21 US US10/505,279 patent/US20050255111A1/en not_active Abandoned
- 2003-02-21 CA CA002476832A patent/CA2476832A1/en not_active Abandoned
- 2003-02-21 JP JP2003569230A patent/JP2005528343A/ja active Pending
- 2003-02-21 IL IL16360503A patent/IL163605A0/xx unknown
- 2003-02-21 RU RU2004128238/15A patent/RU2315621C2/ru not_active IP Right Cessation
-
2004
- 2004-08-20 TN TNP2004000160A patent/TNSN04160A1/en unknown
- 2004-09-21 NO NO20043960A patent/NO20043960L/no not_active Application Discontinuation
- 2004-09-21 CO CO04093610A patent/CO5611170A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2315621C2 (ru) | 2008-01-27 |
| AU2003206571A1 (en) | 2003-09-09 |
| NZ535199A (en) | 2006-03-31 |
| TNSN04160A1 (en) | 2007-03-12 |
| CO5611170A2 (es) | 2006-02-28 |
| AP2004003113A0 (en) | 2004-09-30 |
| MXPA04008061A (es) | 2005-06-20 |
| EP1476186A1 (en) | 2004-11-17 |
| CN1646162A (zh) | 2005-07-27 |
| NO20043960L (no) | 2004-11-10 |
| KR20050004785A (ko) | 2005-01-12 |
| CA2476832A1 (en) | 2003-08-28 |
| IL163605A0 (en) | 2005-12-18 |
| JP2005528343A (ja) | 2005-09-22 |
| US20050255111A1 (en) | 2005-11-17 |
| WO2003070275A1 (en) | 2003-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gu et al. | Reduction of the inflammatory response in patients undergoing minimally invasive coronary artery bypass grafting | |
| Theroux et al. | Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. | |
| AU2004216823B2 (en) | Pharmaceutical preparations containing thiazolidinediones for the treatment or prevention of IP-10 mediated diseases | |
| KR20060123483A (ko) | 허혈성 병변의 치료 및 예방을 위한 트레프로스티닐의 용도 | |
| RU2002127804A (ru) | Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения | |
| RU2004128238A (ru) | Применение ингибитора или антагониста тканевого фактора | |
| Nenci | Dermatan sulphate as an antithrombotic drug | |
| JP2001089382A (ja) | 早期血管再生及び低分子量ヘパリン投与による不安定冠動脈疾患の治療方法 | |
| WO2008002283A2 (en) | Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism | |
| Jeon et al. | Rhabdomyolysis associated with single-dose intravenous esomeprazole administration: A case report | |
| EP3308780B1 (en) | Niclosamide derivatives for inhibiting platelet aggregation | |
| ATE348149T1 (de) | Isolated islets, comprising insulin producing cells, coated with heparin | |
| Ljungström | Invited commentary: Pretreatment with dextran 1 makes dextran 40 therapy safer | |
| Brommer | The effect of ticlopidine upon platelet function, haemorrhage and post-operative thrombosis in patients undergoing suprapubic prostatectomy | |
| RU2147230C1 (ru) | Способ профилактики тромбоэмболических осложнений у хирургических больных | |
| Pannett et al. | Accidental intra‐arterial injection of methylphenidate into the radial artery. | |
| Rivera-Gonzalez et al. | Use of sublingual nitrates for management of limb ischemia secondary to inadvertent intra-arterial buprenorphine/naloxone (Suboxone®) film injection | |
| Helvaci et al. | SAMPLE COPY | |
| Helvaci | Specialist of Internal Medicine, MD, Turkey. Clin Case Rep and Ther Insi 1 (1): 1-13 | |
| da Costa Palmeira | New Work: Balancing People and Performance in the Age of AI. Clin Case Rep and Ther Insi 1 (1): 1-13 | |
| RU2487664C1 (ru) | Способ гизатуллина т.р. определения оптимального объема инфузионной терапии для пострадавших при отморожениях в состоянии наркотического опьянения при употреблении дезоморфина | |
| Hong-bin et al. | Clinical study on effect of osteoking in preventing postoperational deep venous thrombosis in patients with intertrochanteric fracture | |
| EP1752147A4 (en) | MEDICAMENT FOR THE PREVENTION OR TREATMENT OF DIABETES | |
| JPWO2003099324A1 (ja) | 組織因子阻害剤中和剤及び活性型血液凝固第ｖｉｉ因子製剤中和剤 | |
| JP2008532952A (ja) | 高血圧治療のための薬剤の製造における塩酸の適用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20090222 |